Anticancer Res

1. SAMBATARO D, Gebbia V, Scrima F, Borsellino N, et al
   Exploratory Analysis of Dunning-Kruger Effect Among Oncologists Managing Prostatic Adenocarcinoma Candidates for Radionuclide Therapy.
   Anticancer Res. 2025;45:5743-5751.
   

   >> Share

   
   
2. KUO JH, Ou YC, Hu CY, Wu KY, et al
   Optimizing Biopsy Decisions in PI-RADS 3-4 Lesions: Integrating PSA-derived Biomarkers to Reduce Unnecessary Procedures.
   Anticancer Res. 2025;45:5709-5720.
   

   >> Share

   
   
3. ONISHI K, Nakai Y, Miyake M, Matsumura Y, et al
   Should Upfront Therapy With Androgen Receptor Signaling Inhibitors Be Used in All Japanese Patients With Metastatic Castration-sensitive Prostate Cancer?
   Anticancer Res. 2025;45:5595-5607.
   

   >> Share

   
   
4. ASANO Y, Han Q, Li S, Sato T, et al
   Rapid Eradication of Extensive Spinal Metastases in a Prostate-Cancer Patient Taking Androgen-deprivation Therapy, Chemotherapy, and Oral Recombinant Methioninase on a Low-Methionine Diet.
   Anticancer Res. 2025;45:5799-5805.
   

   >> Share

   
   

   
   BMC Urol

5. HALBICH JG, Sigle A, Jogho G, Farin-Glattacker E, et al
   PRE-POET: a qualitative interview-based study to explore patient-relevant factors in the context of prostate biopsy.
   BMC Urol. 2025;25:299.
   

   >> Share

   
   

   
   Br J Cancer

6. WIDDING JL, Stroomberg HV, Dalton SO, Brasso K, et al
   The association between lower urinary tract symptoms and urinary tract infections, and subsequent prostate cancer workup: a nationwide population-based case-control study.
   Br J Cancer. 2025 Dec 3. doi: 10.1038/s41416-025-03288.
   

   >> Share

   
   

   
   Cancer Lett

7. MATOS AC, Lima M, Miranda-Goncalves V, Indraccolo S, et al
   Overcoming Radioresistance in Prostate Cancer by Targeting DNA Damage Repair.
   Cancer Lett. 2025 Nov 28:218183. doi: 10.1016/j.canlet.2025.218183.
   

   >> Share

   
   

   
   Clin Cancer Res

8. SAYEGH N, Graf RP, Swami U, Ozay ZI, et al
   Additive Clinical Utility of Microsatellite Instability and Tumor Mutational Burden to Predict Immune Checkpoint Inhibitor Effectiveness in Metastatic Castration-Resistant Prostate Cancer.
   Clin Cancer Res. 2025 Dec 4. doi: 10.1158/1078-0432.CCR-25-2750.
   

   >> Share

   
   
9. MEDINA S, Tokuyama N, Hammouda K, Pathak T, et al
   A Computational Pathology Model to Predict Docetaxel Benefit in Localized High-Risk and Metastatic Prostate Cancer.
   Clin Cancer Res. 2025 Dec 1. doi: 10.1158/1078-0432.CCR-25-3327.
   

   >> Share

   
   
10. MORRIS MJ, Flynn J, Zhao B, Anand A, et al
    Automated imaging as an adjunct to serum and clinical biomarkers: a new validated prediction tool for metastatic castration-resistant prostate cancer.
    Clin Cancer Res. 2025 Dec 1. doi: 10.1158/1078-0432.CCR-25-2890.
    

    >> Share

    
    

    
    Eur J Radiol

11. EHRENGUT C, Alberalar ND, Franz T, Horn LC, et al
    Evaluation of the TARGET score for MRI-based detection of prostate cancer recurrence in patients treated with HIFU hemiablation.
    Eur J Radiol. 2025;195:112572.
    

    >> Share

    
    

    
    Int J Cancer

12. 
    RETRACTION: Hsp27 Regulates EGF/beta-Catenin Mediated Epithelial to Mesenchymal Transition in Prostate Cancer.
    Int J Cancer. 2025 Dec 3. doi: 10.1002/ijc.70279.
    

    >> Share

    
    

    
    Int J Radiat Oncol Biol Phys

13. YASAR B, Chapman E, Taylor H, Parker C, et al
    Predictors of long-term disease-free survival with stereotactic body radiotherapy for metachronous oligometastatic prostate cancer.
    Int J Radiat Oncol Biol Phys. 2025 Nov 29:S0360-3016(25)06527.
    

    >> Share

    
    
14. FERREIRA CA, Potluri HK, Tantawy AA, Massey C, et al
    Enhanced Antitumor Efficacy of (225)Ac-NM600 Compared to (177)Lu-NM600 in Murine Prostate Cancer Models.
    Int J Radiat Oncol Biol Phys. 2025 Nov 28:S0360-3016(25)06341.
    

    >> Share

    
    

    
    Int J Urol

15. BASARAN E, Hacioglu C
    Abiraterone Acetate Triggers ER Stress-Mediated Androgen Receptor Suppression via PERK/ATF4/CHOP Signaling in Prostate Cancer.
    Int J Urol. 2025 Dec 3. doi: 10.1111/iju.70304.
    

    >> Share

    
    
16. MITSUNARI K, Nakamura Y, Imamura R
    Editorial Comments on the Preliminary Analysis of Prostate Cancer Screening Results and Exploration of a Screening Model for Elderly Males in Rural Areas of Songjiang District, Shanghai.
    Int J Urol. 2025 Dec 3. doi: 10.1111/iju.70308.
    

    >> Share

    
    

    
    J Nucl Med

17. KOEHLER D, Shenas F, Sauer M, Apostolova I, et al
    PSMA PET Evaluation with a Deep Learning Platform Compared with a Standard Image Viewer and Histopathology.
    J Nucl Med. 2025 Oct 16:jnumed.125.270242. doi: 10.2967/jnumed.125.270242.
    

    >> Share

    
    

    
    Prostate

18. MUKHTAROVA G, Murat A, Biray Avci C, Acikgoz E, et al
    Megalin (LRP2) Expression Patterns in Prostate Cancer Stem Cells and Metastatic Subtypes: Implications for Tumor Progression and Metabolism.
    Prostate. 2025 Dec 3. doi: 10.1002/pros.70105.
    

    >> Share

    
    
19. LI J, Wu Y, Hou J, Liu H, et al
    A Comparative Study of the Global Burden of Prostate Cancer (1990-2021): Emphasis on the Disparities Between the United States and China.
    Prostate. 2025 Dec 2. doi: 10.1002/pros.70104.
    

    >> Share

    
    
20. AHMED AE, Dahman B
    Beyond Baseline: Serial PSA Measurements and Risk Stratification for Prostate Cancer.
    Prostate. 2025 Dec 1. doi: 10.1002/pros.70101.
    

    >> Share

    
    
21. WENZEL M, Wurnschimmel C, Nathan A, Moschovas MC, et al
    Robot-Assisted Salvage Prostatectomy: External Validation of the EAU Selection Criteria and Identification of the Optimal Candidate: A Junior ERUS/YAU Collaborative Study.
    Prostate. 2026;86:3-11.
    

    >> Share

    
    
22. BAYANI R, Kolahdouzan K, Nayebirad S, Nabian N, et al
    Hormone Therapy With Salvage Radiotherapy After Radical Prostatectomy: A Systematic Review and Meta-Analysis.
    Prostate. 2026;86:94-104.
    

    >> Share

    
    
23. RAHBAR K, Rosin RD, Kidd M, Halim AB, et al
    PROSTest, a Multigene Liquid Biopsy Signature, Effectively Stratifies Patients With High PSA for Prostate Biopsy.
    Prostate. 2026;86:43-52.
    

    >> Share

    
    

    
    Semin Oncol

24. SU P, Xu Q, Wang Y, Xie W, et al
    Submicron silica particles drives prostate cancer aggressiveness via lipid-metabolic reprogramming.
    Semin Oncol. 2025;53:152433.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share